Correction: Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial

Jessica Ailani1, Peter McAllister2, Paul K. Winner3, George Chakhava4, Mette Krog Josiassen5, Annika Lindsten5, Bjørn Sperling5, Anders Ettrup5 and Roger Cady6,7*

Correction: BMC Neurol 22, 205 (2022)
https://doi.org/10.1186/s12883-022-02714-1

Following publication of the original article [1], the authors identified an error in Figs. 1 and 2. The correct figures are given below.

The original article [1] has been updated.
Fig. 1  Time Course to Headache Pain Freedom (A), Headache Pain Relief (B), and Absence of MBS (C). *$P < 0.05$, **$P < 0.01$, ***$P < 0.001$ vs placebo in analysis censoring for use of rescue medication. The teal/gray bars represent the percentage of patients achieving headache pain freedom (A), headache pain relief (B), and absence of MBS (C) without rescue medication use prior to the achievement. The white bars represent the percent of patients achieving headache pain freedom (A), headache pain relief (B), and absence of MBS (C) regardless of rescue medication use.
Fig. 2 Time Course to Absence of Photophobia (A), Phonophobia (B), and Nausea (C). *P < 0.05, **P < 0.01, ***P < 0.001 vs placebo in analysis censoring for use of rescue medication. Analyses were conducted in patients experiencing the corresponding symptom with their qualifying migraine. The teal/gray bars represent the percentage of patients achieving absence of photophobia (A), phonophobia (B), and nausea (C) without rescue medication use prior to the achievement. The white bars represent the percent of patients achieving absence of photophobia (A), phonophobia (B), and nausea (C) regardless of rescue medication use.

Reference